AZD7325 Japan Multiple Ascending Dose (MAD) Study

Model scores of the 29,894 trials active now.

Model score 6% for any early termination, 0% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 5% of the time (4,470 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2009-11-30. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Accepts healthy volunteers: Yes (lowers risk) · Who can join
• Minimum age: 20 (lowers risk) · Who can join
• Phase: 1 (lowers risk) · Design
• Design: single group (raises risk) · Design
• Responsible party: not given (raises risk) · Design
• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: tolerabilityascendingsubjectsthe safetydoses
  Phrases that lowered it: dayhealthyjudged byas judgedvolunteer
• Has a data monitoring committee: not given (lowers risk) · Design
• Trials the sponsor started in the prior 2 years: 351 (raises risk) · Sponsor's track record
• Number of arms: 4 (lowers risk) · Design
• Drug's FAERS reports with a death: no FAERS history (raises risk) · Drug's FDA history
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Sponsor's past trials: 648 (raises risk) · Sponsor's track record
• Sponsor's past termination rate: 6.8% (lowers risk) · Sponsor's track record
• Drug's FAERS reports marked serious: no FAERS history (raises risk) · Drug's FDA history
• Disease area, cancer: No (lowers risk) · Disease area
• Blinding: quadruple (raises risk) · Design
• Primary purpose: basic science (raises risk) · Design
• Maximum age: 45 (raises risk) · Who can join
• Sex: male (lowers risk) · Who can join

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• AZD7325 Single Ascending Dose Study in Healthy Male Japanese Subjects NCT00769899 · started 2008 · scored riskier than 33% of active trials completed
• AZD2624 Multiple Ascending Dose Study in Japan NCT00696865 · started 2008 · scored riskier than 14% of active trials completed
• AZD9742 Single and Multiple Ascending Dose Study in Healthy Male and Female Japanese Subjects NCT01114152 · started 2010 · scored riskier than 49% of active trials completed
• Study to Investigate Safety, Tolerability and PK Following Single and Multiple Ascending Doses of AZD7295 in Japanese NCT00818129 · started 2008 · scored riskier than 15% of active trials completed
• A Study to Evaluate Safety and Tolerability After Single Oral Dosing of AZD1656 in Japanese Healthy Volunteers NCT00741689 · started 2008 · scored riskier than 9% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.